Hostname: page-component-78c5997874-xbtfd Total loading time: 0 Render date: 2024-11-07T13:29:08.842Z Has data issue: false hasContentIssue false

Psychopharmacological factor in the course of COVID-19 among psychiatric inpatients

Published online by Cambridge University Press:  27 August 2024

M. Sorokin
Affiliation:
1V.M.Bekhterev National Medical Research Centre for Psychiatry and Neurology, St. Petersburg, Russian Federation
A. Shabelnik
Affiliation:
1V.M.Bekhterev National Medical Research Centre for Psychiatry and Neurology, St. Petersburg, Russian Federation
M. Bocharova*
Affiliation:
1V.M.Bekhterev National Medical Research Centre for Psychiatry and Neurology, St. Petersburg, Russian Federation 2King’s College London, London, United Kingdom
N. Lutova
Affiliation:
1V.M.Bekhterev National Medical Research Centre for Psychiatry and Neurology, St. Petersburg, Russian Federation
O. Limankin
Affiliation:
3St. Petersburg Psychiatric Hospital No. 1 named after P.P. Kashchenko 4North-Western State Medical University named after I.I. Mechnikov
L. Azarova
Affiliation:
3St. Petersburg Psychiatric Hospital No. 1 named after P.P. Kashchenko
N. Neznanov
Affiliation:
1V.M.Bekhterev National Medical Research Centre for Psychiatry and Neurology, St. Petersburg, Russian Federation 5FSBEI HE I.P. Pavlov SPbSMU MOH Russia, St. Petersburg, Russian Federation
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

It is known that many psychopharmacological drugs have anti-inflammatory, as well as antibacterial and antiviral effects.

Objectives

To investigate the association between the severity and duration criteria of COVID-19 with psychopharmacotherapy in double-diagnosed patients.

Methods

A total of 169 case histories from a specialized infectious psychiatric department (May 2020 to January 2021) were evaluated. Progression indicators of severe and mild COVID-19, along with the duration of persistent SARS-CoV-2 viral shedding, were assessed in correlation with the administration of antidepressants, antipsychotics, and acid sphingomyelinase inhibitors (FIASMA-active drugs).

Results

The use of any psychotropic agents was associated with a 0.9% increase in the risk of severe course of COVID-19 for each unit increase in the systemic inflammation index PLR, specifically in patients with intellectual disability (ICD-10 codes F70-79), when compared to patients with schizophrenia (ICD-10 codes F20-29): R²McF=0.138; AIC=181; χ²=25.8; df=9; p=0.002. High PLR values and the use of FIASMA-active drugs were associated with prolonged COVID-19 duration, while antidepressant therapy and elevated C-reactive protein levels were associated with a reduced predicted duration of viral shedding in 13.8% of variance: R²=0.0864; AIC=1299; F=5.2(3), p=0.002. Including the nosology of psychiatric disorders in the regression model increased the proportion of explained variance to 22.8%.

Conclusions

Thymoanaleptic therapy for individuals with psychiatric disorders may act as a protective factor against COVID-19. There is no evidence suggesting adverse effects of antipsychotics on the severity and duration of COVID-19. Further research is necessary to investigate the effects of FIASMA-active psychopharmacological agents within nosologically homogeneous groups.

Disclosure of Interest

None Declared

Type
Abstract
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2024. Published by Cambridge University Press on behalf of European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.